Get the Stockscreener App
1.58
8.22%
0.12
Pliant Therapeutics Inc stock is traded at $1.58, with a volume of 1.48M.
It is up +8.22% in the last 24 hours and up +35.04% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.46
Open:
$1.45
24h Volume:
1.48M
Relative Volume:
1.28
Market Cap:
$96.99M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5113
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+0.64%
1M Performance:
+35.04%
6M Performance:
-85.30%
1Y Performance:
-88.99%
1-Day Range:
$1.4477
$1.645
1-Week Range:
$1.4477
$1.645
52-Week Range:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.58 | 89.62M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
What is the risk reward ratio of investing in Pliant Therapeutics Inc. stockRetirement Planning Tips With Low Risk - jammulinksnews.com
What is Pliant Therapeutics Inc. company’s growth strategyBreakout Stocks Picks For Every Investor - jammulinksnews.com
Pliant Therapeutics Inc. Trading Near Value Zone — Recovery AheadTop Performing Stock Insights Released Daily - metal.it
What are analysts’ price targets for Pliant Therapeutics Inc. in the next 12 monthsAdvanced Screener Planner For 2025 - jammulinksnews.com
Competitive Positioning of Pliant Therapeutics Inc.: Is It Leading or LaggingWeekly Return Pick Forecast Reports Show Trend - metal.it
Bollinger Bands Expand on Pliant Therapeutics Inc. — Volatility AheadWatchlist for Smart Swing Trading Updated - beatles.ru
Will Pliant Therapeutics Inc. stock split in the near futureInvestment Playbook for Growing Markets Shared - metal.it
Pliant Therapeutics Inc. Sees Spike in Bullish Option FlowDaily Momentum Screener With Alerts Launched - metal.it
What catalysts could drive Pliant Therapeutics Inc. stock higher in 2025Unprecedented profit potential - jammulinksnews.com
Pliant Therapeutics Inc. Added to High Probability Setup ListLow Risk High Return Opportunities Identified - metal.it
What is the dividend policy of Pliant Therapeutics Inc. stockFree Trading Psychology Coaching - jammulinksnews.com
Is it the right time to buy Pliant Therapeutics Inc. stockHigh-octane financial growth - jammulinksnews.com
What are Pliant Therapeutics Inc. company’s key revenue driversCapitalize on stocks with high profit margins - jammulinksnews.com
Does Pliant Therapeutics Inc. stock perform well during market downturnsGet professional guidance for market timing - jammulinksnews.com
How many analysts rate Pliant Therapeutics Inc. as a “Buy”Capitalize on strategic market trends - jammulinksnews.com
Pliant Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Stock Market Practical Discussion Forums - beatles.ru
What makes Pliant Therapeutics Inc. stock price move sharplyHigh-octane investment opportunities await - jammulinksnews.com
What drives Pliant Therapeutics Inc. stock priceExplosive trading opportunities - PrintWeekIndia
How high can Pliant Therapeutics Inc. stock price go in 2025Explosive wealth accumulation - jammulinksnews.com
What analysts say about Pliant Therapeutics Inc. stockOutperformance with explosive growth - jammulinksnews.com
Pliant Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com
Is Pliant Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Is Pliant Therapeutics Inc. stock a growth or value playHigh Return Potential - Newser
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):